AnaptysBio, Inc (ANAB) stock
ANABNasdaqPharmaceutical PreparationsFiscal year ends June 30
$49.24+2.63 (+5.64%)
Close on Oct 19, 2026Market cap $1.73BP/E –Yield –
AnaptysBio profit margin
Profit margin (net margin) is net income as a percentage of revenue.
AnaptysBio's profit margin for the twelve months ending Sep 30, 2026 was 96.3%. For fiscal 2025 it was -5.6%, against -159.1% the year before. The highest annual figure on record is -5.6% in fiscal 2025.
Annual profit margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -5.6% | +153.5 |
| FY2024 | Dec 31, 2024 | -159.1% | +794.6 |
| FY2023 | Dec 31, 2023 | -953.7% | +297.7 |
| FY2022 | Dec 31, 2022 | -1251.3% | −1159.8 |
| FY2021 | Dec 31, 2021 | -91.5% | −64.9 |
| FY2020 | Dec 31, 2020 | -26.6% | +1190.1 |
| FY2019 | Dec 31, 2019 | -1216.7% | +16.4 |
| FY2018 | Dec 31, 2018 | -1233.1% | −932.4 |
| FY2017 | Dec 31, 2017 | -300.7% | −275.2 |
| FY2016 | Dec 31, 2016 | -25.5% | +5.2 |
| FY2015 | Dec 31, 2015 | -30.8% | – |
Quarterly profit margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | 12.8% | −7.0 |
| Q2 FY2026 | Jun 30, 2026 | 668.9% | +842.5 |
| Q1 FY2026 | Mar 31, 2026 | -206.9% | −65.3 |
| Q4 FY2025 | Dec 31, 2025 | 45.8% | +96.4 |
| Q3 FY2025 | Sep 30, 2025 | 19.8% | +129.2 |
| Q2 FY2025 | Jun 30, 2025 | -173.5% | +251.8 |
| Q1 FY2025 | Mar 31, 2025 | -141.6% | +470.4 |
| Q4 FY2024 | Dec 31, 2024 | -50.5% | +418.2 |
| Q3 FY2024 | Sep 30, 2024 | -109.4% | +1015.0 |
| Q2 FY2024 | Jun 30, 2024 | -425.3% | +726.3 |
| Q1 FY2024 | Mar 31, 2024 | -612.0% | +2608.9 |
| Q4 FY2023 | Dec 31, 2023 | -468.8% | −80.8 |
| Q3 FY2023 | Sep 30, 2023 | -1124.4% | +1466.6 |
| Q2 FY2023 | Jun 30, 2023 | -1151.6% | +1525.5 |
| Q1 FY2023 | Mar 31, 2023 | -3220.9% | +516.7 |
| Q4 FY2022 | Dec 31, 2022 | -388.0% | +2830.4 |
| Q3 FY2022 | Sep 30, 2022 | -2591.0% | −2559.1 |
| Q2 FY2022 | Jun 30, 2022 | -2677.1% | −2675.7 |
| Q1 FY2022 | Mar 31, 2022 | -3737.6% | −3576.1 |
| Q4 FY2021 | Dec 31, 2021 | -3218.4% | −3274.5 |
| Q3 FY2021 | Sep 30, 2021 | -31.9% | +23.2 |
| Q2 FY2021 | Jun 30, 2021 | -1.4% | +674.0 |
| Q1 FY2021 | Mar 31, 2021 | -161.5% | +317.7 |
| Q4 FY2020 | Dec 31, 2020 | 56.1% | +375.2 |
| Q1 FY2020 | Mar 31, 2020 | -55.1% | +173.6 |
| Q4 FY2019 | Dec 31, 2019 | -675.4% | −637.1 |
| Q2 FY2019 | Jun 30, 2019 | -479.2% | −313.0 |
| Q3 FY2018 | Sep 30, 2018 | -319.2% | – |
| Q4 FY2017 | Dec 31, 2017 | -228.7% | – |
| Q2 FY2017 | Jun 30, 2017 | -38.3% | – |
| Q4 FY2016 | Dec 31, 2016 | -166.2% | – |
See a number that looks wrong?